Targenta Ltd has developed an online medical service for patients with a known or suspected medical diagnosis which helps to navigate in the labyrinth of private medical services. We would like to offer our expertise, the power of our proprietary databases and our robust software solutions to find the truly relevant local examinations, healthcare providers, and diagnostic methods for a given complex medical condition.

We take patients’ general physical state, chronic co-morbidities, health insurance options, tax refund status, possible implants, and special sensitivities into consideration, which personalization saves the patients countless dead-ends on the traditionally crooked patient pathway and ultimately, worrying, time and money.

Our mission and vision are to help patients and their families to live longer and higher-quality lives by providing personalized, interactive medical maps covering their relevant opportunities and to provide a platform for the emerging Central and Eastern European medical service market to show its excellent qualities and extensive opportunities to all Customers in Europe.

Our main services are Personal Medical Condition Summaries and Personalized Medical Reports.

Personal Medical Condition Summaries convert the User’s medical and associated data to a 1-pager format synopsis with which one can easily find any medical specialist, since it includes every information needed for a briefing before an examination but doesn’t contain any unnecessary data that would distract or otherwise hamper the process.

Personalized Medical Reports contain the following elements: a map which shows the relevant local services, and a modular list of services with the following crucial info: service price, detailed contact info (link and phone numbers), is it diagnostics or treatment, how invasive it is, is hospitalization needed or not, etc. For detailed info on this topic visit our Services page here

Personalized Medical Reports may come with an expert validation or can be supplemented with written or oral report explanation, medical report translation, and other customary services. For the list of supplementary services visit our Services page here

• To patients and their families, who would like to save time and money

• Patients who would like to avoid dead-ends, unnecessary information, and charlatans

• To patients who are tired of the gratitude money system and would like to use clean services instead of hoping for privileged treatment

• Patients whose problem needs quicker solutions than what government institutes are able to provide

• Patients and relatives who experience communication gaps with medical personnel

• Those who are willing to experience technologically advanced, quality solutions

• Targeted drug combination therapy design based on driver genes. Zsákai L et al., Oncotarget, 2019

• Novel compounds reducing IRS-1 serine phosphorylation for treatment of diabetes. Simon-Szabó L et al., Bioorg Med Chem Lett. 2016

• Complex regulation of autophagy in cancer – integrated approaches to discover the networks that hold a double-edged sword. Kubisch J et al., Sem Cancer Biol. 2013

• Developing FGFR4 inhibitors as potential anti-cancer agents via in silico design, supported by in vitro and cell-based testing. Ho HK et al., Curr Med Chem. 2013

• Mycobacterium tuberculosis ellenes hatoanyagok fejlesztése es szerkezet-hatás összefuggéseinek vizsgálata. Baska F et al., Acta Pharm Hung. 2013

• SignaLink 2 – a signaling pathway resource with multi-layered regulatory networks. Fazekas D et al., BMC Syst Biol. 2013

• Potenciális antitumor hatású FGFR inhibitorok fejlesztése, Zsákai L et al., Acta Pharm Hung. 2013

• WO2017153789: Benzo[b]thiophene derivatives and their use for the inhibition of Fibroblast Growth Factor Receptor kinases (FGFRs) for the use of neo- and hyperplasia

• WO2015019121: Styrylquinazoline derivatives as pharmaceutically active agents

• P1500431: Pyrido pyrimidine derivatives as pharmaceutically active agents

• P1500620: Novel use of kinase antagonist compounds to alter fibrotic cell proliferation

• Placental Galectins Are Key Players in Regulating the Maternal Adaptive Immune Response. Balogh et al., Frontiers in Immunology, 2019

• A versatile modular vector set for optimizing protein expression among bacterial, yeast, insect and mammalian hosts. PLoS One, 2019

• CR3 is the dominant phagocytotic complement receptor on human dendritic cells. Sándor et al., Immunobiology, 2013

• Cutting Edge: A New Player in the Alternative Complement Pathway, MASP-1 Is Essential for LPS-Induced, but Not for Zymosan-Induced, Alternative Pathway Activation. Paréj et al., Journal of Immunology, 2014

• Dissociation and re-association studies on the interaction domains of mannan-binding lectin (MBL)-associated serine proteases, MASP-1 and MASP-2, provide evidence for heterodimer formation. Paréj et al., Molecular Immunology, 2014

• The control of the complement lectin pathway activation revisited: both C1-inhibitor and antithrombin are likely physiological inhibitors, while α2-macroglobulin is not. Paréj et al., Molecular Immunology, 2013

• A novel drug discovery concept for tuberculosis: Inhibition of bacterial and host cell signalling. Székely R et al., Immunology Letters, 2008

• Regulation of influenza A virus mRNA splicing by CLK1. Artarini A et al., Antiviral research 2019

• Investigation of the mode of action of sunitinib kinase inhibitor profile analogues in insulin release. Orfi Z et al. European Journal of Cancer, 2014

• Protein kinase inhibitor-induced endothelial cell cytotoxicity and its prediction based on calculated molecular descriptors. E Herczenik, Z Varga, D Erős, V Makó, M Oroszlán, S Rugonfalvi-Kiss: Journal of Receptors and Signal Transduction 29 (2), 75-83, 2009

• Binding specificity of the L-arginine transport systems in mouse macrophages and human cells overexpressing the cationic amino acid transporter hCAT-1. Erős D et al., Amino acids, 2009

• Signal transduction therapy with rationally designed kinase inhibitors. Keri G et al., Current Signal Transduction Therapy, 2006

• Signalling inhibitors against Mycobacterium tuberculosis--early days of a new therapeutic concept in tuberculosis. Hegymegi-Barakonyi B et al., Curr Med Chem. 2008;15(26):2760-70

• Targeted drug combination therapy design based on driver genes, Zsákai L et al., Oncotarget, 2019

• Reliability of logP predictions based on calculated molecular descriptors: A critical review. Erős D et al, Curr. Med. Chem. 2002

• Evaluation of lipophilicity and antitumour activity of parallel carboxamide libraries. Hollósy F et al., Journal of Chromatography B, 2002

• Relationship between lipophilicity and antitumor activity of molecule library of Mannich ketones determined by high- performance liquid chromatography, clogP calculation and cytotoxicity test. Hollósy F et al., Journal of Chromatography B, 2002

• Evaluation of hydrophobicity and antitumor activity of a molecule library of Mannich ketones of cycloalkanones. Hollósy F et al., Journal of Liquid Chromatography and Related Technologies, 2002

• Biological activity and structure of antitumor compounds from Plantago media. Kunvari M et al., Acta Pharmaceutica Hungarica, 1999

• Comparison of Predictive Ability of Water Solubility QSPR Models Generated by MLR, PLS and ANN Methods. Erős D et al., Mini-Reviews in Medicinal Chemistry 2004

• Determination of the basicity of Mannich ketones by capillary electrophoresis. Dobos Zs et al., Journal of Chromatography B, 2004

• Comparison of measured and calculated lipophilicity of substituted aurones and related compounds. Hallgas B et al., Journal of Chromatography B, 2004

• Rational Drug Design and Signal Transduction Therapy. Erős D et al., Pharmacem, 2004

• Synthesis of selective SRPK-1 inhibitors: novel tricyclic quinoxaline derivatives. Szekelyhidi Z et al., Bioorg Med Chem Lett. 2005 Jul 1;15(13):3241-6.

• Characterization of lipophilicity and antiproliferative activity of E-2-arylmethylene-1-tetralones and their heteroanalogues. Hallgas B et al., J Chromatogr B Analyt Technol Biomed Life Sci. 2005

• Prediction oriented QSAR modelling of EGFR inhibition. Szantai-Kis C et al., Curr. Med. Chem., 2006

• MIF tautomerase inhibitor potency of alpha,beta-unsaturated cyclic ketones. Garai J et al., Int Immunopharmacol.

• Binding mode analysis and enrichment studies on homology models of the human histamine H4 receptor. Kiss R et al., Eur J Med Chem. 2007

• Drug discovery in the kinase inhibitory field using the Nested Chemical Library technology. Kéri G et al., Assay Drug Dev Technol. 2005

• Structure –Activity Relationships of PDE5 Inhibitors. Erős D et al., Current Medicinal Chemistry, Volume 15, Number 16, 2008. Pp. 1570-1585.

• Binding specificity of the L-arginine transport systems in mouse macrophages and human cells overexpressing the cationic amino acid transporter hCAT-1. Erős D et al., Amino Acids. 2009

• Protein kinase inhibitor-induced endothelial cell cytotoxicity and its prediction based on calculated molecular descriptors. Herczenik E et al., Journal of Receptors and Signal Transduction, 2009

• Tyrosine kinase inhibitors - small molecular weight compounds inhibiting EGFR. Hegymegi-Barakonyi B et al., Curr Opin Mol Ther. 2009

• EP3056202: Benzopyrolidone derivatives possessing antiviral and anticancer properties

• Cell-type specific arousal-dependent modulation of thalamic activity in the lateral geniculate nucleus. Molnár et al., Cerebral Cortex Communications, 2021

• Reciprocal lateral hypothalamic and raphé GABAergic projections promote wakefulness. Gazea et al., The Journal of Neuroscience, 2021

On technical issues, please contact us via admin@targenta.org

On medical and business issues, please contact Lilian ZSÁKAI: lilian.zsakai@targenta.org, +36304284142

• On legal and accountancy issues please contact us via admin@targenta.org or via post

• our Szeged Headquarters: H-6726, 11/D Alsó Kikotő sor, Szeged, Hungary

• our Budapest office: H-1074, 9. I.4. Barát str, Budapest, Hungary

Full name: Targenta Korlátolt Felelősségű Társaság

Year of establishment: 2019

Registered seat: H-6726, 11/D Alsó Kikötő sor, Szeged, Hungary

VAT number: 27285736-2-06

Main activity: 7219 Other research and experimental development on natural sciences and engineering